US 11,725,052 B2
Anti-PAR-2 antibodies and methods of use thereof
Anna Mikaela Bracken, Lane Cove (AU); Adam Clarke, Riverstone (AU); Bridget A. Cooksey, Curl Curl (AU); Anthony Gerard Doyle, Macquarie Park (AU); Mark Terence Liddament, Victoria (AU); Matthew Pollard, Pullenvale (AU); Lynn Poulton, Macquarie Park (AU); Anna Maria Matilda Quigley, Macquarie Park (AU); Julia Rozenfeld, Macquarie Park (AU); and Marta Szabat, Vancouver (CA)
Assigned to Cephalon LLC, West Chester, PA (US)
Filed by Cephalon LLC, West Chester, PA (US)
Filed on Aug. 18, 2021, as Appl. No. 17/405,275.
Claims priority of provisional application 63/067,259, filed on Aug. 18, 2020.
Prior Publication US 2022/0056125 A1, Feb. 24, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); C12P 21/06 (2006.01); C12N 5/02 (2006.01); C12N 15/00 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07H 21/04 (2006.01); C07K 16/28 (2006.01); A61P 17/10 (2006.01); A61P 29/00 (2006.01); A61P 35/04 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 17/10 (2018.01); A61P 29/00 (2018.01); A61P 35/04 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 26 Claims
 
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to human protease activated receptor 2 (PAR-2) and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of:
(a) SEQ ID NOs: 10, 11, 12, 16, 17, and 18, respectively;
(b) SEQ ID NOs: 7, 8, 9, 13, 14, and 15, respectively;
(c) SEQ ID NOs: 10, 11, 12, 16, 19, and 18, respectively;
(d) SEQ ID NOs: 10, 11, 12, 16, 29, and 18, respectively; or
(e) SEQ ID NOs: 10, 11, 12, 16, 22, and 18, respectively.